Takeda and PeptiDream Expand $3.5B Collaboration to Develop Peptide-Drug Conjugates for Neurodegenerative Diseases

On July 27, PeptiDream and Takeda announced the expansion of their exclusive collaboration to develop peptide-drug conjugates (PDCs) targeting central nervous system (CNS) targets. Under the terms of the agreement, PeptiDream is eligible to receive total potential payments of approximately $3.5 billion, including an upfront payment and potential preclinical, development, regulatory approval, and sales-based milestone payments.

PeptiDream and Takeda initially entered into an exclusive collaboration and license agreement in December 2020, under which peptides developed by PeptiDream and JCR Pharmaceuticals are conjugated with Takeda-developed payloads targeting human transferrin receptor 1 (TfR1) to form peptide-drug conjugates (PDCs) for the treatment of neuromuscular diseases. This new collaboration expands the application of TfR1-binding peptide ligands to the treatment of neurodegenerative diseases.

A major challenge in developing novel therapeutics for neurodegenerative diseases is the ability to deliver drug molecules across the blood-brain barrier into the brain. Peptide carriers that bind to TfR1 facilitate the transport of potent therapeutic payloads across the BBB into the brain, enabling widespread biodistribution within the brain and significantly improving therapeutic benefits, which is frequently required for the effective treatment of many neurodegenerative diseases.

PeptiDream Inc.'s proprietary Peptide Discovery Platform System (PDPS) is an advanced, highly versatile discovery platform capable of efficiently generating highly diverse (trillion-scale) non-standard peptide libraries to identify potent and selective hit candidates, which can subsequently be developed into peptide-based, small molecule, or peptide-drug conjugate therapies.

Note: The original text has been abridged.